AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$BMRN

Davis George Eric sold $1.2M of BMRN

Davis George Eric (EVP, Chief Legal Officer) sold 17,557 shares of BIOMARIN PHARMACEUTICAL INC (BMRN) at $66.28 ($1.16M total) on 2026-09-02.

Original reporting
SEC EDGAR · Davis George Eric
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BMRN
Bearish
medium confidence
Mentioned
$BMRN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BMRNBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short-term positioning.

02

Market read

Insider sale adds modest negative pressure on BMRN; limited broader market effect.

03

What to watch

No 10b5-1 plan and the officer's role may suggest a strategic move unrelated to fundamentals.

Relevance 6/10Novelty 7/10Timing: Filed after market close on 2026-09-02

Background

Form 4 filings disclose insider transactions; traders monitor them for sentiment cues.

Company-level read

Ticker impact

$BMRNBearishMedium confidence
Context

EVP and Chief Legal Officer Davis George Eric sold 17,557 shares for $1.16M, reducing his stake to 61,003 shares.

Expected impact

Possible modest downside of 1-2% over the next few days.

Evidence & confidence

The sale size is moderate for a senior officer; no 10b5-1 plan indicates discretionary action.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common and not sector-wide.

Regional

U.S. market only; no regional ripple.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be for personal liquidity and not reflect company outlook.

Key entities

  • Company
    Biomarin Pharmaceutical Inc

    US-listed biotech firm (ticker BMRN).

  • Individual
    Davis George Eric

    EVP and Chief Legal Officer of Biomarin.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BMRN insider trading history →

Related articles

OCT 16
$BMRNMed

BioMarin Stock Surges As Wall Street Redraws The Map

BioMarin Pharmaceutical (BMRN) shares rose following a Buy rating from UBS, which cited undervaluation relative to 2027 earnings. The FDA submission for Voxzogo's label expansion and positive clinical data also boosted investor confidence. The company's revenue growth and higher guidance indicate traction in rare-disease drugs, but margin pressure and acquisition financing costs remain concerns.

tipranks.com2 min
OCT 9
$BMRNMedAI 8/10

BioMarin to present data on achondroplasia treatment at ASBMR

BioMarin Pharmaceutical Inc. (BMRN) will present data from 13 studies at the ASBMR 2026 Annual Meeting, including new imaging results for VOXZOGO in treating achondroplasia. The company submitted a supplemental NDA for VOXZOGO to treat hypochondroplasia and expects a 2027 launch if approved. BioMarin also announced data on BMN 333 and BMN 401. VOXZOGO is currently approved in the U.S., Japan, and Australia for achondroplasia.

investing.com1 min
OCT 9
$BMRNMed

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Pharmaceutical Inc. (BMRN) presented new data at the American Society for Bone and Mineral Research 2026 Annual Meeting, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia. The data showed encouraging imaging results from a trial evaluating VOXZOGO's effect on the growth of the foramen magnum and craniocervical junction in children with achondroplasia.

prnewswire.com2 min
OCT 6
$BMRNMed

BIOMARIN PHARMACEUTICAL INC (BMRN): Results of Operations and Financial Condition

BIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition Estimated Financial Impact of the Alesta Acquisition In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid),

SEC EDGAR 8-K2 min